MA26680A1 - Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number: MA26680A1
Authority: MA; Morocco
Prior art keywords: alcynyl; quinolein; substitute; derivatives; preparation
Prior art date: 1998-08-27

Application number

MA25743A

Other languages

English (en)

Inventor

Deborah La Greca Susan

Peter Lyssikatos Joseph

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-25

Publication date

2004-12-20

1999-08-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA26680A1 publication Critical patent/MA26680A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA25743A 1998-08-27 1999-08-25 Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant MA26680A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9814598P	1998-08-27	1998-08-27

Publications (1)

Publication Number	Publication Date
MA26680A1 true MA26680A1 (fr)	2004-12-20

Family

ID=22267481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25743A MA26680A1 (fr)	1998-08-27	1999-08-25	Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (40)

Country	Link
US (3)	US6150377A (fr)
EP (1)	EP1107963B1 (fr)
JP (1)	JP3495706B2 (fr)
KR (1)	KR20010072991A (fr)
CN (1)	CN1314904A (fr)
AP (1)	AP2001002079A0 (fr)
AT (1)	ATE321037T1 (fr)
AU (1)	AU4925499A (fr)
BG (1)	BG105365A (fr)
BR (1)	BRPI9913138B8 (fr)
CA (2)	CA2578326C (fr)
CO (1)	CO5130017A1 (fr)
CZ (1)	CZ2001660A3 (fr)
DE (1)	DE69930518T2 (fr)
DZ (1)	DZ2880A1 (fr)
EA (1)	EA200100135A1 (fr)
EE (1)	EE200100118A (fr)
ES (1)	ES2259237T3 (fr)
GE (1)	GEP20033001B (fr)
GT (1)	GT199900140A (fr)
HK (1)	HK1039123A1 (fr)
HR (1)	HRP20010142A2 (fr)
HU (1)	HUP0103228A3 (fr)
ID (1)	ID27562A (fr)
IL (1)	IL141239A0 (fr)
IS (1)	IS5818A (fr)
MA (1)	MA26680A1 (fr)
NO (1)	NO20010964L (fr)
NZ (1)	NZ509372A (fr)
OA (1)	OA11645A (fr)
PA (1)	PA8480101A1 (fr)
PE (1)	PE20000986A1 (fr)
PL (1)	PL346426A1 (fr)
SK (1)	SK2442001A3 (fr)
SV (1)	SV1999000141A (fr)
TN (1)	TNSN99162A1 (fr)
TR (1)	TR200101343T2 (fr)
UY (1)	UY25682A1 (fr)
WO (1)	WO2000012499A1 (fr)
ZA (1)	ZA200101173B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) *	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
IL141239A0 (en) *	1998-08-27	2002-03-10	Pfizer Prod Inc	Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
DE69923849T2 (de) *	1998-08-27	2006-01-12	Pfizer Products Inc., Groton	Quinolin-2-on-derivate verwendbar als antikrebsmittel
TR200201296T2 (tr)	1999-02-11	2002-07-22	Pfizer Products Inc.	Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (fr)	2000-02-24	2007-10-17	Janssen Pharmaceutica N.V.	Regime posologique contenante inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer
JO2361B1 (en)	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US7196094B2 (en)	2000-09-25	2007-03-27	Janssen Pharmaceutica, N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7053105B2 (en)	2000-09-25	2006-05-30	Janssen Pharmaceutica, N.V.	Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2001293829A1 (en)	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
US7067531B2 (en)	2000-09-25	2006-06-27	Angibaud Patrick Rene	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
DE60139080D1 (de)	2000-11-21	2009-08-06	Janssen Pharmaceutica Nv	Farnesyltransferase hemmende benzoheterocyclische derivate
WO2002050058A1 (fr) *	2000-12-19	2002-06-27	Pfizer Products Inc.	Formes cristallines de sels de 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinoleine-2-one, 2,3-dihydroxybutanedioate et procede de preparation
DE60117847T2 (de) *	2000-12-27	2006-11-16	Janssen Pharmaceutica N.V.	Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
WO2002056884A2 (fr) *	2001-01-22	2002-07-25	Schering Corporation	Traitement du paludisme au moyen d'inhibiteurs de la farnesyl proteine transferase (fpt)
PL208238B1 (pl) *	2001-03-12	2011-04-29	Janssen Pharmaceutica Nv	Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) *	2001-04-06	2002-10-21	Schering Corporation	Treatment of malaria with farsenyl protein transferase inhibitors
US20050165053A1 (en) *	2001-06-04	2005-07-28	Cytovia, Inc.	Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6713462B2 (en)	2001-06-21	2004-03-30	Ariad Pharmaceuticals, Inc.	Quinolinones and uses thereof
US6740757B2 (en) *	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
AU2002358677B2 (en)	2001-12-19	2008-02-07	Janssen Pharmaceutica N.V.	1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de)	2002-03-22	2007-07-15	Janssen Pharmaceutica Nv	Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
EP1497295B1 (fr)	2002-04-15	2006-08-16	Janssen Pharmaceutica N.V.	Derives de quinazoline tricylique inhibant la farnesyl transferase substitues avec des imidazoles ou des triazoles a liaison carbone
SI1585743T1 (sl) *	2002-12-19	2007-08-31	Pfizer	Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
CA2546727C (fr)	2003-11-20	2012-10-02	Children's Hospital Medical Center	Inhibiteurs de gtpase et procedes d'utilisation correspondants
WO2005089515A2 (fr) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Procedes de traitement des synucleinopathies
WO2005094830A1 (fr) *	2004-03-30	2005-10-13	Pfizer Products Inc.	Combinaisons d'inhibiteurs de transduction de signaux
JP2008510792A (ja) *	2004-08-26	2008-04-10	ファイザー・インク	タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
SI1784396T1 (sl) *	2004-08-26	2011-03-31	Pfizer	S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
PL1786785T3 (pl) *	2004-08-26	2010-08-31	Pfizer	Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
ME01509B (me)	2004-11-05	2014-04-20	Janssen Pharmaceutica Nv	Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti
US20060107555A1 (en) *	2004-11-09	2006-05-25	Curtis Marc D	Universal snow plow adapter
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
JP2009508809A (ja)	2005-07-29	2009-03-05	チルドレンズホスピタルメディカルセンター	ＲＡＣ−１ＧＴＰａｓｅのＧＴＰａｓｅ阻害因子とその使用方法およびその結晶構造
CN101517068B (zh)	2005-09-07	2017-02-08	安进弗里蒙特公司	活化素受体样激酶‑1的人单克隆抗体
JP5055284B2 (ja)	2005-09-20	2012-10-24	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
JP2009521470A (ja)	2005-12-23	2009-06-04	リンクメディシンコーポレイション	シヌクレイン障害の治療
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
AU2007240437B2 (en)	2006-04-20	2012-12-06	Janssen Pharmaceutica N.V.	Heterocyclic compounds as inhibitors of c-fms kinase
WO2007124319A1 (fr)	2006-04-20	2007-11-01	Janssen Pharmaceutica N.V.	Inhibiteurs de la c-fms kinase
MX2008013990A (es)	2006-05-09	2009-01-29	Pfizer Prod Inc	Derivados de cicloalquilamino acidos.
MX2009001715A (es)	2006-08-21	2009-02-25	Hoffmann La Roche	Terapia tumoral con un anticuerpo anti-vegf.
WO2008112525A2 (fr) *	2007-03-09	2008-09-18	Link Medicine Corporation	Traitement des maladies de surcharge lysosomale
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
WO2009151683A2 (fr)	2008-03-12	2009-12-17	Link Medicine Corporation	Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
DE102008022221A1 (de) *	2008-05-06	2009-11-12	Universität des Saarlandes	Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
NZ593090A (en)	2008-11-13	2013-06-28	Link Medicine Corp	Azaquinolinone derivatives and uses thereof
WO2010099139A2 (fr)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Thérapie anti-cancer combinée
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
AU2011223643A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (fr)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
WO2012116040A1 (fr)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
WO2012149014A1 (fr)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
WO2013166043A1 (fr)	2012-05-02	2013-11-07	Children's Hospital Medical Center	Rajeunissement de cellules précurseurs
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (fr)	2012-08-07	2016-10-05	Janssen Pharmaceutica, N.V.	Procédé pour la préparation de dérivés d'ester hétérocyclique
US9180185B2 (en)	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
PT3385395T (pt)	2015-08-17	2020-05-06	Kura Oncology Inc	Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
WO2017096165A1 (fr)	2015-12-03	2017-06-08	Agios Pharmaceuticals, Inc.	Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
WO2017184968A1 (fr)	2016-04-22	2017-10-26	Kura Oncology, Inc.	Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
US11124839B2 (en)	2016-11-03	2021-09-21	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
WO2018146253A1 (fr)	2017-02-10	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
US9956215B1 (en)	2017-02-21	2018-05-01	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
AU2018225566B2 (en)	2017-02-21	2019-11-07	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
US11291663B2 (en)	2017-08-07	2022-04-05	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (fr)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
KR20210098969A (ko)	2018-11-01	2021-08-11	쿠라 온콜로지, 인크.	파네실트랜스퍼라제 저해제를 사용한 암의 치료 방법
KR20210106513A (ko)	2018-12-21	2021-08-30	쿠라 온콜로지, 인크.	편평 세포 암종을 위한 요법
US20220142983A1 (en)	2019-03-01	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (fr)	2019-03-15	2020-09-24	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
CA3134825A1 (fr)	2019-03-29	2020-10-08	Kura Oncology, Inc.	Procedes de traitement de carcinomes squameux par des inhibiteurs de farnesyltransferase
TW202102218A (zh)	2019-04-01	2021-01-16	美商庫拉腫瘤技術股份有限公司	以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
US20220305001A1 (en)	2019-05-02	2022-09-29	Kura Oncology, Inc.	Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP4013402B1 (fr)	2019-08-16	2024-11-06	Children's Hospital Medical Center	Inhibiteurs de cdc42 pour utilisation dans le traitement de la dépression, de la sarcopénie ou de la fragilité associées à l'âge
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
AU711142B2 (en) *	1995-12-08	1999-10-07	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
IL141239A0 (en) *	1998-08-27	2002-03-10	Pfizer Prod Inc	Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents

1999
- 1999-08-06 IL IL14123999A patent/IL141239A0/xx unknown
- 1999-08-06 CA CA002578326A patent/CA2578326C/fr not_active Expired - Fee Related
- 1999-08-06 BR BRPI9913138A patent/BRPI9913138B8/pt not_active IP Right Cessation
- 1999-08-06 AU AU49254/99A patent/AU4925499A/en not_active Abandoned
- 1999-08-06 ES ES99933084T patent/ES2259237T3/es not_active Expired - Lifetime
- 1999-08-06 AT AT99933084T patent/ATE321037T1/de not_active IP Right Cessation
- 1999-08-06 DE DE69930518T patent/DE69930518T2/de not_active Expired - Lifetime
- 1999-08-06 CN CN99810204A patent/CN1314904A/zh active Pending
- 1999-08-06 EA EA200100135A patent/EA200100135A1/ru unknown
- 1999-08-06 HR HR20010142A patent/HRP20010142A2/hr not_active Application Discontinuation
- 1999-08-06 HU HU0103228A patent/HUP0103228A3/hu unknown
- 1999-08-06 PL PL99346426A patent/PL346426A1/xx not_active Application Discontinuation
- 1999-08-06 EE EEP200100118A patent/EE200100118A/xx unknown
- 1999-08-06 TR TR2001/01343T patent/TR200101343T2/xx unknown
- 1999-08-06 JP JP2000567527A patent/JP3495706B2/ja not_active Expired - Fee Related
- 1999-08-06 ID IDW20010457A patent/ID27562A/id unknown
- 1999-08-06 NZ NZ509372A patent/NZ509372A/en unknown
- 1999-08-06 GE GEAP19995770A patent/GEP20033001B/en unknown
- 1999-08-06 CA CA002341690A patent/CA2341690C/fr not_active Expired - Fee Related
- 1999-08-06 WO PCT/IB1999/001398 patent/WO2000012499A1/fr not_active Ceased
- 1999-08-06 OA OA1200100051A patent/OA11645A/en unknown
- 1999-08-06 KR KR1020017002442A patent/KR20010072991A/ko not_active Ceased
- 1999-08-06 EP EP99933084A patent/EP1107963B1/fr not_active Expired - Lifetime
- 1999-08-06 AP APAP/P/2001/002079A patent/AP2001002079A0/en unknown
- 1999-08-06 CZ CZ2001660A patent/CZ2001660A3/cs unknown
- 1999-08-06 HK HK02100579.7A patent/HK1039123A1/zh unknown
- 1999-08-06 SK SK244-2001A patent/SK2442001A3/sk unknown
- 1999-08-10 PA PA19998480101A patent/PA8480101A1/es unknown
- 1999-08-24 GT GT199900140A patent/GT199900140A/es unknown
- 1999-08-25 TN TNTNSN99162A patent/TNSN99162A1/fr unknown
- 1999-08-25 DZ DZ990180A patent/DZ2880A1/fr active
- 1999-08-25 MA MA25743A patent/MA26680A1/fr unknown
- 1999-08-26 PE PE1999000862A patent/PE20000986A1/es not_active Application Discontinuation
- 1999-08-26 US US09/383,755 patent/US6150377A/en not_active Expired - Lifetime
- 1999-08-27 CO CO99054519A patent/CO5130017A1/es unknown
- 1999-08-27 UY UY25682A patent/UY25682A1/es unknown
- 1999-08-27 SV SV1999000141A patent/SV1999000141A/es not_active Application Discontinuation
2000
- 2000-07-27 US US09/628,039 patent/US6294552B1/en not_active Expired - Lifetime
2001
- 2001-01-19 IS IS5818A patent/IS5818A/is unknown
- 2001-02-12 ZA ZA200101173A patent/ZA200101173B/en unknown
- 2001-02-26 NO NO20010964A patent/NO20010964L/no not_active Application Discontinuation
- 2001-03-20 BG BG105365A patent/BG105365A/xx unknown
- 2001-07-06 US US09/900,401 patent/US6579887B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR9913138B1 (pt)	2013-11-05
HK1039123A1 (zh)	2002-04-12
KR20010072991A (ko)	2001-07-31
US6579887B2 (en)	2003-06-17
NO20010964D0 (no)	2001-02-26
EP1107963B1 (fr)	2006-03-22
HUP0103228A3 (en)	2003-01-28
DE69930518D1 (de)	2006-05-11
JP3495706B2 (ja)	2004-02-09
IL141239A0 (en)	2002-03-10
DE69930518T2 (de)	2006-09-21
PL346426A1 (en)	2002-02-11
WO2000012499A1 (fr)	2000-03-09
IS5818A (is)	2001-01-19
US6294552B1 (en)	2001-09-25
NZ509372A (en)	2003-08-29
BRPI9913138B8 (pt)	2016-05-17
CA2578326C (fr)	2009-11-24
PA8480101A1 (es)	2003-06-30
TR200101343T2 (tr)	2001-09-21
US20020128287A1 (en)	2002-09-12
GT199900140A (es)	2001-02-14
CO5130017A1 (es)	2002-02-27
EA200100135A1 (ru)	2001-08-27
ZA200101173B (en)	2002-04-12
CA2578326A1 (fr)	2000-03-09
JP2002523504A (ja)	2002-07-30
ID27562A (id)	2001-04-12
CZ2001660A3 (cs)	2002-05-15
TNSN99162A1 (fr)	2005-11-10
BR9913138A (pt)	2001-05-08
US6150377A (en)	2000-11-21
GEP20033001B (en)	2003-06-25
EE200100118A (et)	2002-06-17
NO20010964L (no)	2001-04-26
UY25682A1 (es)	2000-03-31
DZ2880A1 (fr)	2003-12-15
EP1107963A1 (fr)	2001-06-20
HRP20010142A2 (en)	2002-02-28
CA2341690A1 (fr)	2000-03-09
SK2442001A3 (en)	2002-10-08
CA2341690C (fr)	2007-04-17
SV1999000141A (es)	2000-07-06
BG105365A (en)	2001-11-30
ATE321037T1 (de)	2006-04-15
OA11645A (en)	2004-11-16
ES2259237T3 (es)	2006-09-16
AP2001002079A0 (en)	2001-03-31
CN1314904A (zh)	2001-09-26
AU4925499A (en)	2000-03-21
PE20000986A1 (es)	2000-09-30
HUP0103228A2 (hu)	2002-02-28

Publication	Publication Date	Title
MA26680A1 (fr)	2004-12-20	Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26558A1 (fr)	2004-12-20	Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26638A1 (fr)	2004-12-20	Derives d'isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26479A1 (fr)	2004-12-20	Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26465A1 (fr)	2004-12-20	Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26624A1 (fr)	2004-12-20	Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26439A1 (fr)	2004-12-20	Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2740136B1 (fr)	1998-01-09	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26468A1 (fr)	2004-12-20	Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26740A1 (fr)	2004-12-20	Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26425A1 (fr)	2004-12-20	Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26505A1 (fr)	2004-12-20	Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26614A1 (fr)	2004-12-20	Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2742148B1 (fr)	1999-10-22	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr)	2004-12-20	Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
FR2794742B1 (fr)	2005-06-03	Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2735777B1 (fr)	1997-09-12	Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA26499A1 (fr)	2004-12-20	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .